We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Analyst

News List

Amgen's quick Aimovig launch boosts blockbuster hopes for Lilly, Teva and Alder: analyst fiercepharma
August 21, 2018
Amgen's migraine prevention drug Aimovig, just approved in May, is riding a rising wave of early demand—and that's a good thing, not just for Amgen and its partner Novartis, but for other forthcoming drugs in the CGRP class, an analyst said Monday.
Analyst chastises Mylan—not known for its transparency—for under-the-radar dealmaking fiercepharma
August 17, 2018
Mylan unveiled plenty of news in its second-quarter earnings release last week, including that its revenues were down year over year and that it was lowering guidance. But there was also some key info it didn’t include.